Business Context and Reporting Period
Xtant Medical Holdings, Inc. (XTNT) filed its Quarterly Report on Form 10-Q for the period ended June 30, 2026. The company is a global medical technology firm focused on orthobiologics and spinal implant fixation systems. As of August 7, 2026, there were approximately 140.3 million shares of common stock outstanding. The company operates as a single reportable segment, with 98% of revenue derived from the United States.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenue | $23.0 million | $43.9 million |
| Gross Profit | $13.3 million | $25.3 million |
| Gross Margin | 57.9% | 57.6% |
| Net Loss | $(9.4) million | $(12.5) million |
| Diluted EPS | $(0.07) | $(0.09) |
| Cash and Cash Equivalents | $9.9 million | $9.9 million (as of period end) |
| Total Debt (Current + Long-term) | $23.0 million | $23.0 million (as of period end) |
| Working Capital | $34.8 million | $34.8 million (as of period end) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 35% year-over-year for the quarter and 36% for the six-month period. This was driven by the absence of $5.6 million in revenue from divested Coflex/CoFix assets and $5.0 million in license revenue (SimpliMax) that did not recur due to reimbursement changes effective January 1, 2026.
- Unusual Item: The company recorded a $5.0 million non-cash charge for the write-off of a distribution agreement deposit paid to Dilon Technologies, Inc. Management determined recovery was not probable.
- Divestiture Proceeds: The company received $10.4 million in cash from the sale of Coflex/CoFix assets and international hardware business to Companion Spine, LLC, which was partially used to repay term debt.
- Margin Compression: Gross margin decreased to 57.9% from 68.6% in the prior year quarter, attributed to the loss of high-margin license revenue and increased inventory charges.
Guidance, Outlook, and Risks
- Strategic Initiatives: The company entered an exclusive distribution agreement with Dilon Technologies for the HEMOBLAST Bellows product, hiring approximately 20 sales personnel. However, supply is dependent on Dilon's manufacturing in France, with uncertainty regarding availability beyond Q3 2026.
- Liquidity: Management believes current cash ($10.2 million) and available credit facilities ($0.7 million remaining) are sufficient to meet requirements through August 2027. However, additional financing may be required sooner if market conditions deteriorate.
- Debt Covenants: The company executed Amendment No. 5 to its credit agreements in August 2026, waiving the minimum net revenue covenant for Q2 2026. Under prior terms, the company would have been in non-compliance. Future principal payments on the term loan have been increased.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the evaluation of inventory net realizable value. Disclosure controls and procedures were deemed ineffective as of June 30, 2026.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the specific terms of the new minimum net revenue covenants established in Amendment No. 5 and the company's ability to meet them in future quarters.
- Inventory Valuation: Review the remediation plan for the material weakness regarding inventory net realizable value and assess the risk of future write-downs.
- Dilon Supply Chain: Confirm the status of the HEMOBLAST Bellows supply chain and the likelihood of securing supply beyond Q3 2026.
- Recurring Revenue: Assess the trajectory of orthobiologics sales to determine if they can offset the permanent loss of Coflex/CoFix and SimpliMax license revenue.
- Cash Burn Rate: Monitor operating cash flow usage, particularly given the $5.0 million Dilon charge and increased sales headcount costs.